FK866 was considered safe and well tolerated and showed potential anti-angiogenic properties and dose-dependent decrease of patient VEGF levels in a Phase I clinical study that treated 24 patients with advanced Cutaneous T-cell Lymphoma (NCT00431912). This evidence concerns the gene VEGFA and primary cutaneous T-cell non-Hodgkin lymphoma.